Parametric Portfolio Associates LLC raised its holdings in Esperion Therapeutics Inc (NASDAQ:ESPR) by 38.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 48,113 shares of the biopharmaceutical company’s stock after purchasing an additional 13,291 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.17% of Esperion Therapeutics worth $1,517,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently modified their holdings of ESPR. Acadian Asset Management LLC purchased a new stake in Esperion Therapeutics during the first quarter worth about $43,000. PNC Financial Services Group Inc. raised its position in shares of Esperion Therapeutics by 32,833.3% in the first quarter. PNC Financial Services Group Inc. now owns 1,976 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,970 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Esperion Therapeutics by 59.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,159 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 808 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Esperion Therapeutics by 68.1% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,348 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 546 shares during the last quarter. Finally, Ancora Advisors LLC acquired a new position in Esperion Therapeutics during the fourth quarter worth approximately $134,000.
Shares of NASDAQ:ESPR opened at $47.64 on Wednesday. Esperion Therapeutics Inc has a 52 week low of $24.82 and a 52 week high of $76.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 2.35. The company’s fifty day moving average is $44.53 and its 200-day moving average is $48.15. The company has a market capitalization of $1.34 billion, a PE ratio of -4.95 and a beta of 2.16.
Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($2.84) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.14) by $0.30. Esperion Therapeutics had a negative net margin of 5,492.02% and a negative return on equity of 627.38%. The company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $0.39 million. During the same quarter in the previous year, the company earned $3.07 EPS. The firm’s revenue for the quarter was down 98.8% compared to the same quarter last year. On average, analysts forecast that Esperion Therapeutics Inc will post -4.95 EPS for the current year.
Several research firms have recently issued reports on ESPR. Stifel Nicolaus reissued a “buy” rating and issued a $75.00 price objective on shares of Esperion Therapeutics in a research report on Friday, June 26th. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Thursday, March 26th. Citigroup increased their price objective on shares of Esperion Therapeutics from $46.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Needham & Company LLC reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, May 7th. Finally, Jefferies Financial Group lowered their target price on shares of Esperion Therapeutics from $85.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $78.50.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Further Reading: How does a dividend reinvestment plan work?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.